These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 34219)

  • 21. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA; Morris JG; Reid WG; Trafficante R
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Abnormal involuntary movements in the elderly and their treatment (author's transl)].
    Delwaide PJ; Desseilles M
    Sem Hop; 1978 Nov 18-25; 54(41-42):1247-9. PubMed ID: 32624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
    Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apomorphine and diphasic dyskinesia.
    Durif F; Deffond D; Dordain G; Tournilhac M
    Clin Neuropharmacol; 1994 Feb; 17(1):99-102. PubMed ID: 8149366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.
    Bennett JP; Landow ER; Dietrich S; Schuh LA
    Mov Disord; 1994 Jul; 9(4):409-14. PubMed ID: 7969207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Buccofacial dyskinesia of iatrogenic origin].
    Reynes P; Guichard M; Guiraud P
    Rev Odontostomatol (Paris); 1983; 12(6):461-9. PubMed ID: 6142519
    [No Abstract]   [Full Text] [Related]  

  • 33. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Utility of quetiapine in tardive dyskinesia].
    Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
    Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
    Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P
    Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dyskinetic syndromes in psychiatric patients (author's transl)].
    Lutrand JC; Ducamin JP
    Sem Hop; 1978 Dec 18-25; 54(45-46):1465-8. PubMed ID: 34882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
    Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F; Rosa A; Comoy E
    Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
    Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.